Key regions: Australia, Germany, United Kingdom, United States, France
Taiwan, known for its technological advancements and efficient healthcare system, has been witnessing a steady growth in the Immunosuppressants market.
Customer preferences: Patients in Taiwan suffering from autoimmune diseases such as rheumatoid arthritis, lupus, and psoriasis are the primary consumers of Immunosuppressants. The increasing awareness about these diseases and the availability of advanced treatment options have led to a rise in demand for Immunosuppressants in the country.
Trends in the market: The Immunosuppressants market in Taiwan has been witnessing a shift towards biologic drugs, which are more effective in treating autoimmune diseases. The market has also been witnessing the entry of new players, which has intensified the competition. The shift towards biologic drugs and the growing competition have led to a decrease in the prices of Immunosuppressants in Taiwan.
Local special circumstances: Taiwan has a well-established healthcare system, which provides universal health coverage to its citizens. The government has been taking initiatives to promote the use of generic drugs to reduce healthcare costs. This has led to an increase in the use of generic Immunosuppressants in Taiwan.
Underlying macroeconomic factors: The aging population in Taiwan has been a major driver of the Immunosuppressants market. As the population ages, the prevalence of autoimmune diseases increases, leading to a rise in demand for Immunosuppressants. The increasing healthcare expenditure in Taiwan has also been a contributing factor to the growth of the Immunosuppressants market. In conclusion, the Immunosuppressants market in Taiwan is witnessing a shift towards biologic drugs and an increase in the use of generic drugs. The aging population and the increasing healthcare expenditure in the country are expected to drive the growth of the market in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
